First-pass extracted concept

targeted lipid nanoparticles

Candidate: concept label2 source documents2 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Targeted lipid nanoparticles, synthetic DNA nanocarriers, and viral and non-viral delivery systems have demonstrated the ability to generate functional CAR-T cells without ex vivo manipulation, enabling scalable, on-demand immunotherapy.

Evidence 1Source 1DOI PubMedprovenance

Enabled by advanced delivery systems such as immune-evasive lentiviral vectors and targeted lipid nanoparticles

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1capabilitysupports2026Source 1DOI PubMed

Targeted lipid nanoparticles, synthetic DNA nanocarriers, and viral and non-viral delivery systems have demonstrated the ability to generate functional CAR-T cells without ex vivo manipulation.

Quoted textsource-backed

Targeted lipid nanoparticles, synthetic DNA nanocarriers, and viral and non-viral delivery systems have demonstrated the ability to generate functional CAR-T cells without ex vivo manipulation, enabling scalable, on-demand immunotherapy.

Claim 2enabling delivery modalitiessupports2025Source 2DOI PubMed

Advanced delivery systems including immune-evasive lentiviral vectors and targeted lipid nanoparticles enable in vivo CAR engineering.